TME Pharma completes August financing and publishes cash position

• TME Pharma has completed the fund raise announced last August 25th, receiving €500k in
cash on August 28th in addition to the €1.7M raised end of May
• Cash position €2.35M at end of August
• TME will continue the process of making the organization as cost-efficient as possible
• Lower cost basis model allows TME to attract financing to fund its development of novel
therapies for cancer and eye diseases
• Evaluation of crypto and crypto-related candidates ongoing, with no exposure yet

Berlin, Germany, September 1, 2025, 8.00am CEST – TME Pharma N.V. (Euronext Growth Paris:
ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for
cancer and eye diseases, is pleased to announce that the transaction announced last August 25th has
now been completed with €500k in cash received by the Company August 28th. The cash position of
TME Pharma is up to €2.35M, showing the good progress of the new cost-efficient organization.

Now that TME Pharma has implemented the lower cost-base model, it will be more able to attract
partners for the development of new therapies for cancer and eye diseases. TME Pharma still high
expectations for its NOX-A12 and NOX-E36 programs. TME Pharma will keep informing the markets
about the progress it is making.

CEO Van den Ouden will continue to use his experience and expertise to implement the Company’s
treasury investment strategy to properly balance risk and return to achieve optimal results for
shareholders. TME Pharma is continuing to search for suitable crypto and crypto related candidates
for the treasury investment strategy but has no current exposure to crypto.

For more information, please contact:

TME Pharma N.V.
Diede van den Ouden, CEO
ir@tmepharma.com

About TME Pharma

TME Pharma is a clinical-stage biotechnology company specializing in the development of novel
therapies for cancer and eye diseases. The Company’s lead compounds have been designed to act on
the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection
barriers against the immune system and blocking tumor repair. The Company’s two lead assets are:

• NOX-A12 (olaptesed pegol, an anti-CXCL12 L-RNA aptamer), which is being studied (GLORIA
Phase 1/2 clinical trial) in newly-diagnosed brain cancer patients who will not benefit clinically
from standard chemotherapy. The US FDA and the German BfArM have approved the design
of a randomized Phase 2 trial in glioblastoma, and TME Pharma was awarded Fast Track
Designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for
use in the treatment of the aggressive adult brain cancer, glioblastoma. NOX-A12 in
combination with radiotherapy had also previously received orphan drug designation (ODD)
for glioblastoma in the United States and glioma in Europe.

• NOX-E36 (emapticap pegol, L-RNA aptamer inhibiting CCL2 and related chemokines), which is
being evaluated in ophthalmic diseases with a high need for well-tolerated therapies with anti-
fibrotic effect.
The Company, under the leadership of its new CEO, Diede van den Ouden, who joined in the June
2025, is currently undertaking a strategic restructuring with the goal of providing the financial
resources to unlock the value of NOX-A12 and NOX-E36. These steps include:
• Raising funds from alternative sources (€1.7 million raised in May 2025, including €500,000
from the new CEO)
• Pursuing stable, cash-generating business opportunities to achieve positive operational cash
flow for the Company
• Leveraging tax loss carry forwards
• Gaining exposure to digital assets via newly established crypto brokerage account
Further information can be found at: www.tmepharma.com.


About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination
with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients
with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates
safety and efficacy of NOX-A12 in the expansion arm in which NOX-A12 is combined with radiotherapy
and bevacizumab.


About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12
combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-
paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.


Disclaimer

Translations of any press release into languages other than English are intended solely as a
convenience to the non-English-reading audience. The company has attempted to provide an accurate
translation of the original text in English, but due to the nuances in translating into another language,
slight differences may exist. This press release includes certain disclosures that contain "forward-
looking statements.” Forward-looking statements are based on TME Pharma’s current expectations
and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors
that could cause actual results to differ include, but are not limited to, the risks inherent in oncology
drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain
regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements
contained in this announcement are made as of this date, and TME Pharma undertakes no duty to
update such information except as required under applicable law.